Monday, November 4, 2019

November 04, 2019 at 09:22PM CUVITRU

Product approval information is indicated for replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age and older.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/2WJ3mKO
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)